Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer

Debashis Sarker, Alison H. M. Reid, Timothy A. Yap, Johann S. de Bono

Research output: Contribution to journalArticlepeer-review

309 Citations (Scopus)


Despite recent advances in our understanding of the biological basis of prostate cancer, the management of the disease, especially in the castration-resistant phase, remains a significant challenge. Deregulation of the phosphatidylinositol 3-kinase pathway is increasingly implicated in prostate carcinogenesis. In this review, we detail the role of this pathway in the pathogenesis of prostate cancer and the rapidly evolving therapeutic implications of targeting it. In particular, we highlight the importance of the appropriate selection of agents and combinations, and the critical role of predictive and pharmocodynamic biomarkers.
Original languageEnglish
Pages (from-to)4799 - 4805
Number of pages7
JournalClinical Cancer Research
Issue number15
Publication statusPublished - 1 Aug 2009


Dive into the research topics of 'Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer'. Together they form a unique fingerprint.

Cite this